This committee’s site publishes no list of positions we could read, and we found no statement of why it exists. We do not write one for it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$308K to 114 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $308,000
Democratic 51%
Republican 37%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Democratic
53
$158,500
$0
$158,500
51%
Republican
46
$113,000
$0
$113,000
37%
Other or unresolved
15
$36,500
$0
$36,500
12%
Shown support
114
$308,000
$0
$308,000
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$718,000 in 289 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
53
$158.5K · 22%
Republican candidates
44
$111K · 15%
Other or unresolved candidates
19
$49.5K · 6.9%
Democratic party committees
2
$12K · 1.7%
Other party committees
3
$90K · 12%
Other PACs and committees
55
$299.5K · 42%
All recipients
176
$720.5K
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
California
15
$54.5K
North Carolina
7
$28K
New Jersey
6
$19K
Texas
9
$18K
Pennsylvania
6
$15K
Massachusetts
3
$13.5K
Ohio
5
$13K
Kansas
2
$12.5K
The largest 8 of 37 states.
Recipients 176
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
Don Davis4 receipts, latest Dec 9, 2025Don Davis for NC · H2NC02287$10K
Adam C. Gray4 receipts, latest Jun 2, 2026Adam Gray for Congress · H2CA13115$10K
Troy A. Carter Sr.3 receipts, latest Mar 17, 2026Troy Carter for Congress · H2LA02149$8.5K
Nanette Barragan5 receipts, latest Sep 14, 2026Barragan for Congress · H6CA44103$8K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
Where the money came from $791,503 reported receipts
Itemized (over $200)Donors who have given more than $200 this cycle, so the FEC itemizes (names) them.$500,13163%
Largest donors
Angequita Marie Beeler Highsmith2 contributions, latest Mar 13, 2026 · HEAD POPULATION HEALTH CENTER OF EXCEL · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$10,000
Frederick Bittenbender42 contributions, latest Sep 30, 2026 · HEAD US PUBLIC AFFAIRS · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Elise M. Conner42 contributions, latest Sep 30, 2026 · DIRECTOR · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Kelly S. Frankenreider42 contributions, latest Sep 30, 2026 · REGIONAL VICE PRESIDENT (RVP) CUSTOMER · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Jacquelyn Moore42 contributions, latest Sep 30, 2026 · HEALTHCARE MARKET EXECUTIVE DIRECTOR · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Valerie Reynolds42 contributions, latest Sep 30, 2026 · EXECUTIVE DIRECTOR, USPE · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Joy Maatman Russell42 contributions, latest Sep 30, 2026 · VICE PRESIDENT U.S. EXTERNAL AFFAIRS · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Thomas Stoll42 contributions, latest Sep 30, 2026 · SENIOR DIRECTOR · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Matthew L. Sulkala42 contributions, latest Sep 30, 2026 · DIRECTOR · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Ravi Upadhyay42 contributions, latest Sep 30, 2026 · SENIOR DIRECTOR - FEDERAL GOVERNMENT A · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,736
Rachelle Benson41 contributions, latest Sep 30, 2026 · HEAD OF PRODUCT PUBLIC RELATIONS · GENENTECH USA, INC. · SOUTH SAN FRANCISCO, CA$8,112
Sean A. Johnston25 contributions, latest Jan 30, 2026 · SENIOR VICE PRESIDENT - GENERAL COUNSE · GENENTECH, INC. · SOUTH SAN FRANCISCO, CA$5,200
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 11,788 itemized contributions were filed this cycle, totaling $497.2K. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$233,16429%
TransfersMoney moved in from affiliated committees.$56,7087.2%
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$1,5000.2%
Total reported receipts $791,503
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. Open a source marked + to see who gave. FEC filings through Oct 14, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $497,151 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $19.9K
$19.9K+
$79.5K+
$179K+
$318.2K+
none
Top states
Top donor states
Name
Amount
California11,788 contributions · 100%
$497,151
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
Genentech USA INC9,189 contributions · 80% of ranked
$398,617
Genentech INC2,599 contributions · 20% of ranked
$98,534
Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($233,164) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
SpendingWhere does the money go?
How the spending splits $887,610 reported
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$719,50081%
Paid to
DSCC2 payments · latest Feb 17, 2026 · CONTRIBUTION$30,000
NRSC2 payments · latest Feb 17, 2026 · CONTRIBUTION$30,000
Other disbursementsEverything the committee reports outside the lines above.$160,55018%
Operating expendituresThe committee's own running costs.$7,5600.9%
Paid to
Citibank9 payments · latest Aug 21, 2026 · BANK FEES$7,560
Total reported disbursements $887,610
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $725,560 itemized
Given to othersContributions to other candidates, party committees, and PACs.$718,00099%
Filed as
CONTRIBUTION$718,000
Paid to
DSCC$30,000
NRSC$30,000
NRCC$30,000
Scalise Leadership Fund$12,000
Elect Democratic Women$10,000
I GOT Your Back PAC$10,000
Taxes, fees, and bank chargesPayroll and income taxes, filing fees, bank and merchant processing charges.$7,5601%
Filed as
BANK FEES$6,470
BANK FEE$1,090
Paid to
Citibank$7,560
Total itemized disbursements $725,560
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 298 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
Largest vendors
Largest vendors
Name
Spending over time
$891.1K spent from Jan 2025 to Oct 2026. Most in one report: $102.5K, September 2025.
$891.1K
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Besides giving through its PAC, Genentech, Inc. pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$8.9M
Quarterly reports read
62
Bills it named
12
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Health Issuesin 48 report entries · 3 bills named
In its own words
Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives.
Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars.
General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
Issues related to healthcare legislation Patient access to Part B medicines Issues related to health equity, diversity, and inclusion in clinical trials Issues related to advanced development and procurement of medical countermeasures (MCMs) Issues related to patient assistance and access Issues relating to privacy and securing the data of and personal information of consumers Issues relating to medical research data Issues relating to screening and diagnostics Issues related to public health preparedness and response Issues related to awareness about diabetic eye diseases in minority populations Issues related to public health preparedness.
Issues related to access to drugs for minority communities Issues related to healthcare education and screening
340B Program issues and patient access to pharmaceuticals.
Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy.
Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains.
Enhanced FDA reporting and risk mitigation plans for certain medicines.
Incentives for antimicrobial and antiviral research, medical countermeasures, and novel product development.
Issues related to drug pricing.
Issues related to the 340B Drug Discount Program.
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement;
Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease;
Issues relating to privacy and securing the data of and personal information of consumers General education on policies effecting development of pharmaceuticals, FDA approval and reimbursement.
Issues related to antimicrobial resistance and infectious disease.
Issues related to public health preparedness including the SNS and supply chain.
Issues related to awareness about diabetic eye diseases.
Issues related to privacy and consumer information.
Medical research data.
Issues related to public health preparedness.
Issues related to access to drugs for minority communities.
Issues related to healthcare education and screening.
Issues related to 340B Reform;
H.R.9599, SECURE 340B Act.
Issues related to PBM Reform.
Issues related to public health preparedness. Issues related to access to drugs for minority communities. Issues related to healthcare education and screening. Issues related to 340B Reform. Issues related to PBM Reform.
Medicare/Medicaidin 27 report entries · 5 bills named
In its own words
Issues related to Medicare and Medicaid coverage and reimbursement;
Issues related to Most Favored Nation (MFN) drug pricing proposal;
H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act;
Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program;
H.R. 1672, Maintaining Investments in New Innovation Act;
Issues related to Senate Finance Dear Colleague process;
H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Issues related to Senate Finance Dear Colleague process
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.
Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299).
Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Policies related to the Most Favored Nation Drug Pricing Model.
Issues pertaining to 340B;
Issues related to drug importation;
Issues related to prescription drug pricing;
Issues related to the International Pricing Index for Medicare Part D;
Budget/Appropriationsin 14 report entries
In its own words
Issues related to FDA and HHS program funding for the FY25 Labor, HHS, Education and Related Agencies, and FY25 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicineS Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance Deficit reduction, reconciliation
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Appropriations and budget issues including: LHHS-Ed, Ag-FDA, and HHS program funding. Reconciliation and deficit reduction.
Appropriations relating to pandemic influenza.
Federal budget issues
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
White House Office
Copyright/Patent/Trademarkin 14 report entries · 3 bills named
In its own words
Intellectual property and process patent issues Patent litigation reforms PTAB and IPR processes Section 101 Reform Domestic and international compulsory licensing issues March-in Rights
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to IP and patent policy reform. Issues related to FDA regulation and drug development including PDUFA and biosimilars.
Taxation/Internal Revenue Codein 13 report entries · 1 bill named
In its own words
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97);
Issues related to tax;
Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97);
Issues related to the Medicaid Drug Rebate Program.
Issues related to R&D tax deductions and expense amortization Issues related to international taxation, including foreign-derived intangible income and interest deductions Issues related to supply chain incentives
Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income). P.L. 119-21.
Issues related to tax exempt hospitals and charity care. Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Issues related to tax exempt hospitals and charity care.
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Issues related to the 340B program.
Drug pricing issues Prescription Drug User Fee Act reauthorization Issues related to prescription drug value Issues related to the 340B Drug Discount Program
Issues related to drug pricing. H.R.4299/S.__ - Protecting Patient Access to Cancer and Complex Therapies Act.
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver Issues related to compulsory licensing of foreign patents Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
Issues related to intellectual property rights in foreign countries.
Issues related to tariff and trade policy.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
U.S. Trade Representative (USTR)
Patent & Trademark Office (PTO)
Manufacturingin 7 report entries
In its own words
Issues related to pharmaceutical supply chains Issues related to reporting on location of origin of pharmaceutical products Issues related to drug shortages Issues related to pharmaceutical manufacturing
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Who did the lobbying
The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.
Reported twice a year by the lobbying filer. $149.5K is political giving that also appears in FEC filings.
Rep. Tom Emmer (MN-06)$16K
Sen. Steven Daines (R-MT)$12.5K
Rep. French Hill (AR-02)$10K
Sen. John Cornyn (R-TX)$9K
Rep. Kevin Hern (R-OK-01)$8K
Candidate Kurt Alme (R-MT)$6K
Rep. Max Miller (OH-07)$5.5K
Sen. John Barrasso (R-WY)$5K
Candidate Mike Rogers (R-MI)$3.5K
Rep. Ashley Hinson (R-IA-02)$3.5K
Matched by name: these reports are filed for “GENENTECH, INC.”, found by searching “GENENTECH”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Oct 26, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
GENENTECH INC. POLITICAL ACTION COMMITTEE (GENENPAC)
Filings covered
Through Oct 14, 2026
Data source
FEC bulk filing data
Genentech Inc. PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Genentech Inc. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Pages quoted 0 pages
No pages quoted
Nothing from this committee’s or its sponsor’s site is quoted yet.
Linked public records
No approved organization identity yet
The official FEC committee record remains available under Filings.
$720.5K across 179 recipient committees, or 81% of everything this committee reports spending. The largest 12 are shown.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
Occupation as filed
Amount
Director449 contributions · 7.2% of ranked
$31,703
Director Healthcare Market (HD)1,009 contributions · 6.5% of ranked
$28,623
Senior Director140 contributions · 3.9% of ranked
$17,154
Healthcare Market Executive Director127 contributions · 2.7% of ranked
$11,805
Executive Director Uspe42 contributions · 2% of ranked
$8,736
Head US Public Affairs42 contributions · 2% of ranked
$8,736
Regional Vice President (RVP) Customer42 contributions · 2% of ranked
$8,736
Senior Director - Federal Government A42 contributions · 2% of ranked
$8,736
Ranked from the largest 200 of 201 occupation spellings filed; each share is of the money in those. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($233,164) are not itemized, so no employer or occupation is filed for them.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
Issues related to prescription drug user fee agreement;
Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97);
Issues related to pharmacy benefit managers;
Issues related to the Medicaid Drug Rebate Program.
Issues related to 340B;
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements.
Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.